Outcomes of irinotecan-based chemotherapy regimens in elderly medicare patients with metastatic colorectal cancer

Conclusions: The definitive survival advantage of irinotecan observed in clinical trials was not reproducible in this population of elderly Medicare patients. The results emphasize the need for expansion of trials to include a more diverse patient group as well as continued evaluation of more recent chemotherapies in real-world settings.